CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
EXPAREL +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02128646
NCT02128646Phase 4Completed
CompareCT.gov

Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

University of Kansas Medical Center·interventional·Posted May 1, 2014·Updated Sep 10, 2025

In Brief

A Phase 4 clinical trial evaluating EXPAREL, Ketorolac, and 2 other interventions for Pain. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally invasive) abdominal hernia repair surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
CollaboratorsPacira Pharmaceuticals, Inc

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 1, 2014
Enrollment StartApr 1, 2014
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.2 years ago

Interventions

EXPARELdrug

Ketorolacdrug

laparoscopic abdominal hernia repairprocedure

an open surgery for abdominal hernia repairprocedure